Annals of Oncology 1994: Vol 5 Index

25 Pages·1994·4.9 MB·English

Annals of Oncology 5: 967-982, 1994.
Index of subjects Volume 5 (1994)
(Abstract Supplements 5 and 8 not included)
A allogeneic bone marrow transplantation
ABVD and bcl-2 quantification in low-grade lymphoma S1: 43
long-term results in advanced Hodgkin’s disease $2: 53 for myelodysplastic syndrome and secondary leukaemias 401
acquired immune deficiency syndrome (AIDS) alopecia
aetiology of HIV-related lymphoma S2: 29 minoxidil as a prophylaxis 69
and Hodgkin’s disease $2: 37 alpha-fetoprotein
and related lymphoma 487, S2: 29, S2: 41 in advanced hepatocellular carcinoma 646
Epstein-Barr gene expression in AIDS-related non-Hodgkin's in endodermal! sinus tumor and clear cell ovarian cancer 753
lymphomas S1: 113 alpha-interferon (see interferons)
MGBG: results in AIDS-related }ymphomas 487 amiodarone
prognostic factors in HIV-associated lymphomas 487, S2: 41 to overcome MDR 659
acromegaly anaplastic large cell lymphoma
associated with malignancies 659 a distinct clinicopathologic entity $1: 25
activation and CD30 expression 300, 317
of the X chromosome in non-Hodgkin’s lymphomas $1: 47 and degree of anaplastic morphology 317
adaptive dosing in childhood S1: 31
and possible improvement of results $4: 9 long term prognostic importance of primary ki-1 (CD30) antigen
ADEPT expression and anaplastic morphology in adult patients with
antibody directed enzyme prodrug therapy in the treatment of cancer diffuse large-cell lymphoma 317
879 angiogenesis
adjuvant therapy and gene therapy S4: 45
and cardiotoxicity in breast cancer 209 and retinoids $9: 17
chemo- and radiotherapy for biliary and pancreatic cancer S3: 73, clinical prognostic significance 305
$3: 81 angiosarcoma
for breast cancer 717 of the residual breast 163
for colorectal cancer $3: 97 animal model
for gastric cancer $3: 49 for hepatic artery occlusion 961
second malignancies following 785, 803 growth of HD-cell lines in SCID-mice S1: 121
timing of baseline quality of life in breast cancer 65 xenografts and drug screening 396, 415
15 years follow-up of Ludwig I-IV trials 717 anosmia
adverse effects associated with alpha-interferon treatment 863
after long-term 5-FU, prednisone and a-interferon 245 anthracyclines
following emetogenic chemotherapy and ondansetron 98 cardiotoxicity 98
with docetaxel 185 cardiotoxicity after adjuvant breast treatment 196, 209
with paclitaxel 474, 827 FAC and FEC in breast cancer 95
age indium-111 scintigraphy in diagnosis of cardiotoxicity by 617
as prognostic factor in HD S2: 37 randomised trial of epirubicin vs. fluorouracil in advanced gastric
in the treatment of lymphoma (Editorial) 873 cancer 33
alkylating agents anti-angiogenesis
and minor-groove binding (Editorial) 877 and vascular targeting $4: 45
phase I study of the novel distamycin derivative tallimustine 901 in the future of anticancer treatment 305
ALL (see also leukemias) anti-Tac monoclonal anti-body
and acute lysis syndrome 379 and lymphokines $1: 13
heterogeneity in HIV-seropositive patients 437 antibiotics
all-trans-retinoic acid (see also retinoic acid) duration of i.v. treatment for neutropenic fever 441
and teratogenesis S9: 39 antibody-enzyme conjugates
as radiosensitizer S9: 3 in the treatment of cancer 879
combined with c-interferon in cell lines $9: 7 anticancer drugs
combined with radiation in cell lines $9: 3, S9: 7 adapting methodology of phase | trials $4: 67
for differentiation S9: 3, S9: 17 and angiogenesis 305
for growth-inhibition S9: 7 and antisense $4: 55
pharmacokinetic of $9: 33 and immunotargeting 703
968
and novel approaches in therapy 205 and upregulation of epidermal growth factor receptor on human
and possible improvement through pharmacokinetics $4: 9 epithcaencelr icelalsl 2 69
antiemetic AZQ
a phase I of MDL 73,147EF, chemotherapy 549 in human tumor xenograft4s1 5
and vascular toxicity and thrombocytopenia 98
dose-finding study of tropisetron 821 B
new directions in research 569 bel-1
ondansetron and dexamethasone 253 and mantle cell lymphoma 507
oral granisetron alone and in combination with dexamethasone 579 bel-2
state-of-the-art 569 and apoptosis 119
antifolate and solid tumors 388
edatrexate in advanced soft tissue sarcoma 766 before and after allogeneic bone marrow transplantation $1: 43
edatrexate in hepatocellular carcinoma 646 biology of 199, S1: 61
edatrexate in pancreatic carcinoma 286 expression in primary breast cancer 409
antimetabolite intensive conventional-dose chemotherapy for stage IV low-grade
edatrexate in hepatocellular carcinoma 646 lymphoma and to negative of $2: 73
edatrexate in pancreatic adenocarcinoma 286 regulation of chemoresistance by S1: 61
edatrexate in soft tissue sarcoma 766 bel-6
antisense in diffuse large-cell lymphoma S1: 55
a new approach for anticancer drugs S4: 55 biliary cancer
and regulation of chemoresistance by bcl-2 S1: 61 adjuvant radiotherapy and chemotherapy for biliary cancer S3: 75
therapeutic use in lymphoma S1: 67 edatrexate in the treatment of 286
apoptosis biochemotherapy
and expression of bcl-2 in breast cancer 409 with thymosin-a1, IL-2 and dacarbazine in metastatic melanoma 741
and retinoids $9: 3, S9: 17 biological response modifiers
bcl-2 and solid tumours 388 annual review (book) 231
non-Hodgkin's lymphoma and lymphocytic leukemia S1: 61 biology
physiological basis 119 of B- and T-cell lymphomas 689
aredia (see pamidronate) ofb el-2 119, S1: 61
aromatase inhibitors of Hodgkin’s disease $1: 105
basic concepts S7: 3 of primary mediastinal lymphoma 847, 943
formestane vs. tamoxifen in first-line treatment S7: 19 bisphosphonates
in the treatment of advanced postmenopausal breast cancer S7: 7 and delayed progression of bone metastases S7: 41
treatment of advanced breast cancer with formestane S7: 11, S7: 15 and palliation of bone metastases $7: 37, S7: 45
aspergillosis effect on the mechanical properties of canine bone S7: 49
chemoprophylaxis 571 infusion rate and safety $7: 27
asthenia treatment of tumour-induced hypercalcaemia with pamidronate 359
and CSFs 473 bladder cancer
AUC weekly gemcitabine in 182
and teratogenesis of retinoids S9: 39 body composition
limited sampling models for topotecan pharmacokinetics 259 and resting energy expenditure in the treatment of SCLC 915
autologous bone marrow transplantation bone metastases
and PBPC 781, 935 and pamidronate $7: 31, S7: 37, S7: 41
as consolidation therapy for follicular lymphoma S2: 143 bone resorption (see also bisphosphonates)
comparison with peripheral blood stem-cell for lymphoma patients and pamidronate 359
935, $2: 151 brain tumor
consensus conference on 19 concentration of paclitaxel in 951
early in the course of Hodgkin’s disease $2: 161 incidence, and outcome of primary central nervous system lymphomas
for low-grade non-Hodgkin’s lymphoma: the EBMT experience 349
$2: 147 breast angiosarcoma
in breast cancer 674 after conservative surgery and radiotherapy for primary carcinoma 163
in first complete remission for high-grade non-Hodgkin’s lymphoma breast cancer
$2: 155 adjuvant chemohormonal treatment 717
role in Hodgkin's disease $2: 17 adjuvant treatment and cardiotoxicity 209
axillary nodes and angiogenesis 305
current controversies in the surgical management of breast cancer and second malignancies 785, 803
$4: 39 application of molecular genetics to $4: 17
5-aza-2’-deoxycytidine carboplatin and etoposide as first line treatment 858
dose-escalation with G-CSF 217 carboplatin and irradiation in small-cell lung cancer 601
dose-escalation with GM-CSF 43, 709 weekly carboplatin and VM-26 for elderly patients with small-cell
elsamitrucin: a phase II trial 375 lung cancer 369
FAC after FEC 95 cardiac toxicity
FLAC and GM-CSF in the treatment of 217 following adjuvant chemotherapy and breast irradiation 196, 209
formestane in the treatment of $7: 1, $7: 7, S7: 11, S7: 15, $7: 19 high, with a 4-drug combination 641
goserelin with or without tamoxifen in 337 of epirubicin 98
hormonal treatment for 337, 717, S7: 1 usefulness of indium-111 antimyosin scintigraphy in the diagnosis of
in males 83 617
molecular biology of $4: 31 cathepsin D
m-VAC: a phase II study in 93 prognostic value in breast cancer 329
neoadjuvant chemotherapy and radiotherapy in stage IIb, Illa 591 CAV
ovarian ablation vs. goserelin 337 as third-line salvage therapy for Hodgkin's disease 427
palliation with pamidronate $7: 45 CCNDI1
pamidronate in the treatment of S7: 31, S7: 37, S7: 41, S7: 45 cyclin DI overexpression in non-Hodgkin's lymphoma with
preoperative treatment with taxol 863 chromcsome 11 bcl-1 rearrangement $1: 71
prognostic significance of angiogenesis 305 in mantle cell lymphoma 507
prognostic significance of bcl-2 409 CD30
prognostic significance of cathepsin D 329 which is its nature? 300
radiotherapy alone in stage IIb-IIla 591 CD34
rationale of high-dose chemotherapy for 674 positive cells and autografting 935
suramin: a phase II trial 597 CD40
surgical management of $4: 39 to evaluate peripheral blood progenitor cells 781, 795
taxol in the treatment of 863, S6: 17, S6: 23 CDRIII regions
taxotere as second line treatment 527 in B-cell lymphoma S1: 79
timing of QL assessment 65 cell cycle
timing of surgery 25, 29 and apoptosis 119
vinorelbine as first line treatment 854 and bel-1 507, $1: 71
vinorelbine as salvage treatment 423 and bcl-2 388
breast irradiation and retinoids S9: 11, S9: 17
and late cardiotoxicity 209 mechanism of action of paclitaxel $6: 3
bromodeox yuridine centrocytic lymphoma (see also mantle cell lymphoma)
and cell kinetics of human ovarian cancer 627 cyclin D1 overexpression in S1: 71
mantle-cell lymphoma 507, $1: 35
Cc cervical cancer
CABO incidence, mortality and survival in Vaud, Switzerland, 1974-1991 747
vs. CF and cisplatin alone in head and neck tumors 521 chemoresistance
camptothecins regulation by the bcl-2 oncoprotein in non-Hodgkin's lymphoma and
doses, infusions and choice of schedule S4: 25 lymphocytic leukemia cell lines $1: 61
cancer chemotherapy
and angiogenesis 305 a) combination
and palliative treatment (book) 195 a four-drug combination in non-small-cell lung cancer 641
chemotherapy for (book) 231 ABVD in Hodgkin's disease S2: 53
gene transfer in tumor therapy 789 adjuvant chemo-hormonal treatment in breast cancer 717
quality-of-life assessment in palliative care 13 CABO vs. cisplatin vs. CF in head and neck tumors 521
cancer care carboplatin and etoposide in first-line for breast cancer 858
patient participation in the cancer consultation 199 CAV as third-line salvage in HD 427
quality assessment of palliative care 13 CHOEP vs. hCHOP/iVEP in lymphoma 49
cancer-related pain CHOP vs. chlorambucil in low-grade $2: 67
oral tramadol and morphine for 141 CHVmP-VB vs. proMACE-MOPP in lymphoma S2: 85
the fight against it: state-of-the-art 111 dacarbazine and 5-FU in medullary thyroid cancer 763
candidiasis ECF in gastric cancer 609
chemoprophylaxis of fungal infections in neutropenic patients 571 ELF combination in gastric cancer 90
carboplatin epirubicin, cisplatin and 5-FU in gastric cancer 609
carboplatin and paclitaxel in ovarian carcinoma S6: 39 E-SHAP in relapsed non-Hodgkin's lymphoma 453
intraperitoneally in ovarian carcinoma 127, 133 FAC and FEC in breast cancer 95
phase II study with etoposide in metastatic breast cancer 858 5-FU and cisplatin in nasopharyngeal carcinoma 87
randomized comparison of etoposide-cisplatin vs. etoposide 5-FU and folinic acid in gastric cancer 850
5-FU and folinic acid in prostatic cancer 644 and G-CSF 217
5-FU, prednisone and a-interferon in renal cell cancer 245 and GM-CSF 43, 709, $2: 123
MOPP/ABVD in Hodgkin’s disease $2: 53 chemoradiotherapy 513, 591, 771, S3: 9, S3: 17, S3: 81, S3: 87
m-VAC in breast cancer 93 combination chemotherapy vs. cisplatin in head and neck 521
P-VEBEC in elderly patients with lymphoma 895 combined vs. sequential chemoradiotherapy in head-and-neck
randomized study of 2 combinations in non-small-cell lung cancer tumors 513
323 combined with chemotherapy in esophageal carcinoma S3: 9,
randomized study of 4 different combinations in aggressive $3: 17
lymphoma (SWOG-8516) S2: 91 combined with radiotherapy in SCLC 771, 921
taxol in combination in breast cancer S6: 23 combined with radiotherapy in stage IIb-IIla breast cancer 591
three regimens in the treatment of SCLC 921 combined with retinoids $9: 17
VACOP-B in mediastinal lymphoma 943 efficacy in NSCLC 303
VAPEC in lymphoma 147 exacerbation of hepatitis C virus during 861
vinorelbine and cisplatin in NSCLC 37 in the treatment of extragonadal germ cell tumor 225
b) single agents in the treatment of extrapulmonary SCLC 909
2-cDA in CLL and lymphomas 57 in the treatment ofga stric cancer 8, 189
2-cDA in hairy cell leukemia 676, 725 in the treatment of Hodgkin’s disease S2: 17
2-cDA in Waldenstrém macroglobulinemia 288 in the treatment of low-grade lyraphoma $2: 23
cisplatin in mesothelioma 373 in the treatment of mesothelioma 373, 653, 949
edatrexate in hepatocellular carcinoma 646 in the treatment of non-seminomatous germ cell tumors 457
edatrexate in pancreatic cancer 286 long term results in melanoma 249
edatrexate in soft-tissue sarcoma 766 long term results in SCLC 921
elsamitrucin in breast cancer 375 multidisciplinary treatment of lymphoma S2: 5
elsamitrucin in non-small-cell lung cancer 375 multimodality treatment of pancreatic cancer S3: 81, S3: 87
elsamitrucin in ovarian cancer 375 new alkylating agents 877, 901
epirubicin vs. FU in gastric cancer 33 trial H7 in Hodgkin’s disease S2: 107
etoposide: i.v. or oral in gastric cancer 90 childhood
etoposide in hepatoma 466 Hodgkin’s disease in children $2: 113
etoposide in mesothelioma 949 chlorambucil
etoposide in ovarian cancer 656 and prednisone vs. CHOP in low-grade lymphomas S2: 67
fludarabine in CLL and lymphomas S2: 79 2-chlorodeoxyadenosine
gemcitabine in gastric cancer 471 and high incidence of infections 57
gemcitabine in lung cancer 283, 852 and immunodepression 676
gemcitabine in me'anoma 471 in CLL 57
in low-grade lymphoma S2: 23 in hairy cell leukemia 676, 725
MGBG in HIV-related lymphoma 487 in lymphomas 57
oral doxifluridine in colorectal cancer 760 in patients with Waldenstrém macroglobulinemia 288
oral etoposide in hepatomas 466 CHOP
oral etoposide in ovarian cancer 656 vs. CHOP in low-grade lymphoma S2: 67
paclitaxel and docetaxel 495 vs. mBACOD vs. proMACE-cytaBOM vs. MACOP-B in patients with
tallimustine: a phase I 901 intermediate or high-grade non-Hodgkin’s lymphoma S2: 91
taxol in breast cancer 863, S6: 17 CHVmP-VB
taxol in head-and-neck cancer S6: 51 vs. proMACE-MOPP in intermediate- and high-grade lymphoma
taxol in heavily pretreated ovarian cancer 824 $2: 85
taxol in lung cancer S6: 45 cis-retinoic acid (see also retinoic acid)
taxol in multiple myeloma 757 and teratogenesis S9: 39
taxol in ovarian cancer S6: 29, S6: 33, S6: 39, S6: 55 combined with interferon 391
taxotere in breast cancer 527 pharmacokinetic of S9: 33
taxotere in colorectal cancer 468 with interferon in squamous carcinomas 463, S9: 29, S9: 33
taxotere in head and neck cancer 533 cisplatin
taxotere in renal cell cancer 185 and etoposide vs. etoposide-carboplatin in NSCLC 601
vinorelbine in breast cancer 423, 854 and 5-FU in nasopharyngeal carcinoma 87
vinorelbine in HD 817 and vinorelbine vs. vinorelbine alone in advanced non-small cell lung
weekly 5-FU/CF in gastric cancer 850 cancer 37
WM 26 and carboplatin in SCLC 369 in the combination E-SHAP for lymphoma 453
c) general intraperitoneally in gastric cancer 123
and bcl-2 388, S1: 61, $2: 73 vs. combination chemotherapy in head-and-neck tumors 521
and binding of DNA minor-grooves 877 weekly in malignant pleural mesothelioma 373
clinical cases FAC and FEC in breast cancer 95
male breast cancer 83 cytokines
malignant lymphoma vs. sarcoma: discordance between clinical course and gene transfer in tumor therapy 789
and i xcytoch 'y 365 a phase I trial of continuous infusion IL-4 alone and following IL-2
management of advanced colorectal cancer 635 447
management of desmoid tumours including a case report of toremifene CD30 and its nature 300
173 combined with retinoids $9: 17
management of head-and-neck cancer 553 IL-7, IL-8, and TNF receptor in Hodgkin’s disease $1: 93
metastatic tumor of unknown primary site 841 targeting of cytokine gene expression to malignant melanoma cells
the endodermal sinus tumour and clear cell ovarian cancer 753 S4: 59
the management of non-seminomatous germ cell tumours 457 cytotoxicity assay
the management of primary mediastinal B-cell lymphoma with in vitro drug sensitivity testing using the fluorometric microculture
sclerosis 943 $1: 127
tumour-induced hypoglycaemia: a case report 277
CLL D
and cyclin D1 overexpression $1: 71 data management
fludarabine-present status and future developments $2: 79 toxicity grading systems. A comparison between the WHO scoring
clonal evolution system and the common toxicity criteria 113
in relapsing lymphomas S1: 75 delayed emesis
colorectal cancer cisplatin-induced delayed emesis 585
ADEPT treatment in 879 new directions in research 569
adjuvant therapy of S3: 97 ondansetron plus dexamethasone is superior to ondansetron alone 253
and genetics (book) 285 desmoid tumours
management of advanced status 635 management of 173
oral doxifluridine in elderly patients 760 dexamethasone
phase II trial of elsamitrucin 375 combined with granisetron vs. granisetron alone in the prevention of
protracted venous infusion 5-FU and interferon-c in 239 nausea 579
surgery for $3: 91 in the treatment of cisplatin-induced emesis 585
taxotere: a phase II trial 468 plus ondansetron is superior to ondansetron alone in the prevention of
combined modality emesis 253
in early stages of Hodgkin’s disease S2: 101 to prevent taxol hypersensitivity 474
in Hodgkin’s disease of childhood $2: 113 diet
in SCLC 771, 921 and epidemiology of non-Hodgkin’s lymphoma S1: 19
in squamous cell esophageal carcinoma S3: 9, S3: 17 differentiation
in the management of gastric cancer S3: 37 and CD30 300
in the treatment of biliary cancer $3: 73 and retinoids S9:; 3, S9: 17
of locally advanced pancreatic cancer S3: 81 involvement of DNA topoisomerases and DNA _ topoisomerase
predictive role of Gallium scan after S2: 59 inhibitors in 679
preliminary results of H7 protocol for Hodgkin’s disease $2: 107 dipyridamole
the future for the treatraent of lymphoma? S2: 5 biochemical modulation of multidrug resistance 733
treatment of early and intermediate stages of supradiaphragmatic DNA damage
Hodgkin’s disease 809 in apoptosis 119
common toxicity criteria with tallimustine 901
a comparison with the WHO scoring system for nausea and vomiting DNA ploidy
113 and P53 overexpression in human soft tissue sarcomas 167
computer modelling DNA topoisomerase
and discovery of a new anticancer drug S4: 51 involvement in the induction of leukemia cell differentiation 679
consensus conference molecular analysis of topoisomerase II gene in ovarian cancer 75
on intensive chemotherapy plus hematopoietic stem cell transplanta- docetaxel (see also taxotere)
tion in malignancies 19 an active drug for the treatment of patients with advanced squamous
on mantle cell lymphoma 507 cell carcinoma of the head and neck 533
on GI-lymphoma 397 compared to paclitaxel 495
continuous infusion in advanced renal carcinoma 185
of 5-FU compared with bolus 291 in metastatic colorectal carcinoma 468
of 5-FU with epirubicin and cisplatin in gastric cancer 609 in second line treatment for advanced breast cancer 527
cross-resistance dose escalation
between bolus and continuous infusion of 5-FU 291 in breast cancer with G-CSF 217
between taxol and vinorelbine 473 in breast cancer with GM-CSF 43, 709
972
in lymphomas $2: 121, $2: 133 Hodgkin’s lymphoma S2: 47
of taxol in ovarian cancer S6: 39 oral doxifluridine in patients with metastatic colorectal cancer 760
dose intensity P-VEBEC in patients with lymphoma 895
a study of FLAC and GM-CSF in breast cancer 709 weekly carboplatin and VM-26 for patients with SCLC 369
and haemopoietic growth factors in aggressive lymphoma $2: 121, elsamitrucin
$2: 133 phase II studies in breast cancer, colorectal cancer, non-small cell lung
of taxol in ovarian carcinoma S6: 39 cancer and ovarian cancer 375
dose optimization endocrine therapy
can be achieved with pharmacokinetic and pharmacodynamic studies formestaasn eS7 : 1, S7: 11
$4: 9 goserelin as 337
in the use of suramin 597 in adjuvant treatment 717
of tropisetron 821 of breast cancer 337, 717, S7: 1, S7: 11, S7: 15, S7: 19
doxorubicin toremifene in desmoid tumours 173
and drug immunotargeting for carcinomas 703 endodermal sinus tumour
cardiac effects following adjuvant treatment in operable breast cancer and its management 753
209 endonucleases
combination chemotherapy with paclitaxel in metastatic breast cancer and their role in apoptosis 119
$6: 23 endothelium
FAC vs. FEC in breast cancer 95 and angiogenesis 305, S4: 45
indium-111 scintigraphy in diagnosis of cardiotoxicity 617 energy expenditure
prophylaxis of alopecia 769 after hepatic artery occlusion 961
drug design and body composition in the treatment of SCLC 915
discovery of new anticancer drugs by computer-aided drug design epidemiology
$4: 51 of gastric cancer in Ticino 954
new minor-groove binders 877, 901 of invasive cervical cancer in Vaud, Switzerland 1974-1991 747
drug resistance of non-Hodgkin’s lymphoma S1: 19
and bcl-2 388, S1: 61 of primary CNS-lymphoma 349
in vitro drug sensitivity testing of tumor cells from patients with non- epidermal growth factor-receptor
Hodgkin’s lymphoma S1: 127 and upregulation by 5-aza-2’-deoxycytidine 269
molecular analysis of the topoisomerase II-c gene in ovarian cancer 75 epirubicin
P-glycoprotein expression in primary and metastatic transitional cell and cisplatin with 5-FU in gastric cancer 609
carcinoma of the bladder 835 antitumor activity and toxicity 98
drug scheduling FEC for breast cancer 95
can improve therapeutic results? $4: 9 vs. 5-FU in gastric cancer 33
two schedules of etoposide oral or i.v. in ELF 90 Epstein-Barr virus (EBV)
drug screening and the interrelationship between Hodgkin's disease and non-
and xenografts 396, 415, 877 Hodgkin’s lymphomas S1: 7
in Europe 396, 415 in Hodgkin’s disease S1: 105
DTIC in nasal T-cell lymphoma S1: 39
with thymosin-c | and IL-2 in patients with metastatic melanoma 741 latent and replicative gene expression in post-transplant lympho-
dwell-time proliferative disorders and AIDS-related non-Hodgkin's
its influence in intraperitoneal-administered carboplatin in patients lymphomas S1: 113
with ovarian cancer 133 esophageal carcinoma
current status and future directions in the treatment of $3: 27
neoadjuvant therapy for $3: 17
E radiotherapy with or without chemotherapy S3: 9
E-SHAP etiology
in relapsed lymphoma 453 of HIV-related lymphoma S2: 29, S2: 41
EBMT of Hodgkin's disease S1: 105
results in ABMT for high-grade lymphoma $2: 155 of nasal lymphoma S1: 39
results in ABMT for low-grade lymphoma S2: 147 of post-transplant lymphomas S1: 113
edatrexate etoposide
in pancreatic carcinoma: a phase II 286 chronic oral administration in hepatomas 466
in patients with hepatocellular carcinoma: a phase II 646 chronic oral administration in mesothelioma 949
in soft-tissue sarcoma: a phase II 766 chronic oral administration in ovarian cancer 656
elderly combined with carboplatin or cisplatin in NSCLC 601
best treatment for patients with lymphoma 873 doses and scheduling $4: 25
comparable prognostic factors in patients with aggressive non- in combination with carboplatin in breast cancer 858
in the combination E-SHAP in lymphoma 453 G
two administrations in gastric cancer 90 G-CSF
with ELF in gastric cancer 90 after high-dose chemotherapy and autologous peripheral blood
euthanasia progenitor cell transplantation 781, 795
a further comment 378 and dose intensity in lymphoma $2: 13, $2: 133
extragonadal dose escalation in breast cancer 217, 674
malignant germ-cell tumors in females management 225 supporting dose-escalated doxorubicin and ifosfamide in
extrapulmonary mesothelioma 653
small-cell carcinoma: a single-institution experience 909 with P-VEBEC in lymphoma 895
Gallium scan
and magnetic resonance imaging in mediastinal lymphoma 433
F predicts relapse in Hodgkin's disease $2: 59
FAC gastric cancer
dose escalation with G-CSF 217 adjuvant treatment S3: 49
only partial cross-resistance with FEC 95 ECF chemotherapy for 609
feasibility ELF chemotherapy for 90
of quality-of-life assessment in an international study 65 epidemiology in Ticino 954
FEC epirubicin vs. 5-FU 33
only partial cross-resistance with FAC 95 etoposide in 2 schedules for 90
fertility gemcitabine: a phase II trial 471
dose-dependent impairment of testicular function 355 general principles of chemotherapy 8
fever initial or delayed chemotherapy 189
duration of i.v. antibiotics for neutropenic fever 441 intraperitoneal cisplatin in the management 123
FISH preoperative chemotherapy $3: 59
and chromosome analysis of non-Hodgkin’s lymphomas S1: 51 role of radiotherapy S3: 37
in mantle cell lymphoma 507, S1: 35 salvage treatment 850
investigation of activation state of chromosome S1: 47 strategies in the surgical treatment of $3: 33
flow cytometry treatment of localized disease $3: 69
for evaluation of growth-inhibition in follicular lymphomas 265 treatment with supportive care only? 189
for measuring cell kinetics in ovarian cancer 627 weekly high-dose 5-FU and folinic acid 850
fludarabine gastro-oesophageal cancer
and i ppression $2: 79 a phase II study using epirubicin and cisplatin in combination with
in the treatment of CLL and lymphoma S2: 79 continuous infusion 5-FU (ECF) 609
partial cross-resistance with 2-cDA in Waldenstrém macro- gemcitabine
globulinemia 288 in extensive SCLC 283
folinic acid in gastric cancer 471
and 5-FU in hormone-refractory prostatic cancer 644 in head-and-neck tumors 543
and weekly high-dose 5-FU as salvage treatment in advanced gastric in malignant melanoma 471
cancer 850 twice weekly in NSCLC 852
in the adjuvant therapy of colorectal cancer $3: 97 weekly in bladder cancer 182
follicular lymphomas (see lymphomas and non-Hodgkin's lymphomas) gene amplification
formestane and possible therapeutic approaches 205
in advanced breast cancer S7: 1, S7: 11, S7: 15, S7: 19 and retinoids $9: 11
5-FU and the topoisomerase II-a gene 75
and cisplatin in nasopharyngeal carcinoma 87 in breast cancer $4: 17, $4: 37
and folinic acid in gastric cancer 850 in soft tissue sarcomas $4: 17
and high-dose folinic acid in prostatic cancer 644 gene rearrangements
and prednisone/a-interferon in renal cell cancer 245 in follicular lymphomas S1: 61
comparison bolus/continuous infusion 291 in mantle cell lymphomas 507
doses and scheduling $4: 25 in relapsing lymphomas S1: 75
in adjuvant treatment for gastric cancer S3: 49 in solid tumors 388
in adjuvant treatment of colorectal cancer $3: 97 gene therapy
in FAC/FEC for breast cancer 95, 217 and inhibition of angiogenesis $4: 45
in multimodality treatment for pancreatic cancer $3: 73, S3: 81 gene transfer in tumor therapy (Review) 789
vs. epirubicin in gastric cancer 33 in malignant melanoma cells $4: 59
weekly with folinic acid in gastric cancer 850 Second International Conference on Gene Therapy of Cancer
fucosyl-GM (Commentary) 313
in small-cell lung cancer: a comparison with NSE 623 targeting of cytokine gene expression $4: 59
974
germ-cell tumors in the treatment of myelodysplastic syndrome 401
and acute monocytic leukemia 649 hepatic artery
extragonadal malignant germ-cell tumors in females 225 occlusion in rat liver tumour 961
ovarian germ-cell tumors 225 hepatitis-C virus
the management of non-seminomatous germ-cell tumours (GCT) 457 acute exacerbation during chemotherapy and radiotherapy 861
Gl-lymphoma hepatocellular carcinoma
treatment of 397 phase II trial of chronic daily VP-16 466
workshop on pathological and staging classification 397 phase II trial of edatrexate 646
GM-CSF high-dose chemotherapy
a dose intensity study of FLAC chemotherapy and 709 and PBCPs 781, 795
after autologous PBPC transplantation 781 and the role of GM-CSF 663
and dose intensity in lymphoma S2: 13, $2: 133 dose-escalated doxorubicin and ifosfamide/mesna in malignant
failure to permit dose-escalation in advanced breast cancer 43 mesothelioma 653
randomized against placebo with COP-BLAM for lymphomas $2: 123 in breast cancer 43, 217, 674, 709
granisetron in high-grade lymphoma S2: 123, $2: 131, $2: 133, $2: 155
alone and in combination with dexamethasone 579 in low-grade lymphoma S2: 143, $2: 147, $2: 151
new directions in research 569 in older patients with lymphoma S2: 127
growth factors in primary mediastinal lymphoma 943
conference on ‘Growth Factors, Development and Cancer’ summary of consensus conference 19
(Commentary) 575 high-grade lymphoma (see lymphomas)
exploiting tumour biology: novel approaches in cancer therapy histologic transformation
(Commentary) 205 and low-grade lymphoma S2: 23
GVHD and mantle-cell lymphoma 507
and enhanced muco-cutaneous toxicity 377 identification of genetic lesions associated with S1: 55
HIV
H and ALL 437
Ha-ras and breast cancer 661
oncogene-targeted antisense DNA S4: 55 and etiology of lymphomas S2: 29
hairy cell leukemia and HD S2: 37
and 2-cDA 676 and lymphomas S2: 29, S2: 41
long-term results of a-interferon 725 lymphomas and prognostic factors S2: 41
treatment of choice 676 Hodgkin's disease
head-and-neck cancer CAV as salvage treatment 427
a phase II of gemcitabine (LY 188011) 543 clinicopathological features of HIV-related cases $2:37
a randomized study of sequential vs. simultaneous chemoradiotherapy disseminated growth of cell lines in SCID mice $1: 121
513 early bone marrow transplantation in $2: 161
and retinoids 463, $9: 17, S9: 23 early-stage: long-term results with radiotherapy alone or combined
cis-retinoic acid and interferon in the treatment of 463 radiotherapy and chemotherapy S2: 101
docetaxel: an active drug for 533 Gallium scan predicts relapse S2: 59
growth modulation effects of retinoids and interferon on cell lines Hodgkin’s disease in patients with HIV infection 487, $2: 37
$9: 7 hybrid LOPP/EVA is not better than LOPP S2: 117
management of 553 IL-7, IL-8 and TNF receptors in the serum of $1: 93
paclitaxel: a phase II trial S6: 51 interrelationship with non-Hodgkin's lymphomas S1: 7
prevention with retinoids $9: 23, $9: 29 is an infectious disease? S1: 105
randomized comparison of CABO vs. CF vs. cisplatin 521 late mortality in young BNLI patients $2: 65
treatment with PEG-IL-2 957 long-term results with the alternating MOPP/ABVD chemotherapy
Helicobacter pylori $2: 53
and GI-lymphoma 397 MGBG in the treatment of HIV-related cases 487
and the epidemiology of non-Hodgkin’s lymphoma S1: 19 P53 as a marker of the malignant cell S1: 89, S1: 93
hematopoietic stem cell preliminary results of the trial H7 in early-stage S2: 107
consensus conference on intensive chemotherapy plus hematopoietic prognostic factors in 809, $2: 17, S2: 37, $2: 53, $2: 97, $2: 101
stem cell transplantation in malignancies 19 proliferation of Reed-Sternberg cells and variants $1: 117
durability of autografting 935 radiotherapy in early stages 809, S2: 101, S2: 107, S2: 113
hemopoietic growth factors (see also G-CSF and GM-CSF) review of treatment 1993 S2: 17
and dose intensity in high-grade and intermediate-grade lymphoma the quality of life of long-term survivors 153
$2: 123, $2: 131, $2: 133 treatment of early and intermediate supradiaphragmatic stages 809
cost-benefit in older patients with non-Hodgkin's lymphoma S2: 127 vinorelbine: an active drug for 817
in breast cancer 43, 217, 709 with a mediastinal mass greater than 10 cm S2: 97
hospice analysis of the 53 gene in non-Hodgkin's lymphomas $1: 85
and quality-of-life assessment in palliative care 13 lymphoma vs. sarcoma (Clinical cases) 365
5-HT3 receptor antagonist P53 in Hodgkin's disease S1: 89
a phase I study of MDL 73,147EF 549 prognostic value of cathepsin D expression in breast cancer:
gramsetron alone or in combination 579 i histochemical assessment and correlation with radiometric
new directions in research 569 assay of cathepsin D 329
ondansetron alone or in combination 98, 253 immunotargeting
tropisetron: a dose finding study 821 for anticancer drugs 703
HTLV-1 immunotherapy
and lymphokine receptors $1: 13 and gene transfer 789
hybrid chemotherapy IL-2 in renal cell cancer 179
four drug combinations in aggressive lymphomas $2: 91 IL-2, thymosin-c and dacarbazine in melanoma 741
hCHOP/iVEP in high-grade lymphoma 49 IL-4 and IL-2: a phase I study 447
LOPP/EVA is not better than LOPP alternating with EVAP S2: 117 lymphokine recepats oar tarsge t of $1: 13
VAPEC-B in high-grade lymphomas 147 PEG-IL2 treatment of head-and-neck tumors 957
hypercalcaemia immunotoxins
dose of pamidronate 359, S7: 45 is there a clinical value? S1: 97
pamidronate in the treatment of tumour-induced 359 'I![n-antimyosin
hypersensitivity reactions usefulness in confirming myocardial injury with anthracycline-
with docetaxel 185 associated left ventricular dysfunction 617
with paclitaxel 474, 827 incidence
hypoglycaemia of gastric lymphoma in Ticino 954
tumour-induced (Clinical cases) 277 of invasive cervical cancer in Vaud, Switzerland, 1974-1991 747
of non-Hodgkin's lymphoma S1: 19
I of primary central nervous system 349
ifosfamide infection
dose escalated with doxorubicin in mesothelioma 653 high incidence after 2-chlorodeox yadenosine 57
or cisplatin in combination for NSCLC 159 insul-like growth factors
IL-2 tumour-induced hypoglycaemia (Clinical cases) 277
and gene transfer 789 interferon(s)
and release of IL-8 929 and 5-FU in colorectal cancer 239
biology of 119, 789, S1: 113 and prednisone in renal cell cancer 245
in renal cell cancer 179 anosmia associated with 863
with IL-4: a phase I study 447 combination with retinoids 391
with thymosin-c and dacarbazine in melanoma 741 in combination with chemotherapy in lymphoma S2: 73
IL-3 in the treatment of hairy cell leukemia 676, 725
growth inhibition of follicular small-cleaved-cell lymphoma cells 265 with 13-cis-retinoic acid in squamous carcinomas 463
IL-4 with retinoids in general S9: 3, S9: 7, S9: 33
in the serum of patients with Hodgkin’s disease $1: 93 intermediate cell lymphoma (see mantle cell lymphoma)
IL-7 intraperitoneal treatment
in the serum of patients with Hodgkin’s disease S1: 93 and dwell-time 133, 662
IL-8 future prospects 108
and treatment with IL-2 929 in gastric cancer 123
in the serum of patients with S1: 93 in patients with ovarian cancer 127, 133, 343, 662, S6: 55
immune response with carboplatin 127, 133, 662
and aetiology of HD S1: 105 with mitoxantrone 343
immunoconjugates with taxol S6: 55
a reality at last? 703 ischaemia
and future perspectives 697 and hepatic artery occlusion in rat liver tumour 961
lessons from animal models 698 isochromosome
immunodeficiency and acute monocytic leukemia occurring in mediastinal germ cell
and EBV S1: 113 tumour 649
and Hodgkin's disease $2: 37
and lymphoproliferative disorders $1: 113, $2: 29, $2: 41 K
and the interrelationship between Hodgkin's disease and non- Ki-1 lymphoma
Hodgkin’s lymphomas S1: 7 a distinct clinicopathologic entity $1: 25, $1: 31
and lymphoma $2: 29 and CD30 expression 300
yhniu istoc hh © to y in childhood $1: 31
976
long-term prognostic importance of antigen expression and anaplastic CHOEP vs. alternating hCHOP/iVEP in aggressive forms 49
morphology in 317 comparison of ABMT and PCBP in S2: 151
Ki-67 differentiation vs. sarcomas 365
and proliferation of Reed-Sternberg cells and variants in Hodgkin’s dose intensity and CSFs S2: 131, S2: 133
disease S1: 117 EBMT experience with ABMT in high-grade S2: 155
EBMT experience with ABMT in low-grade $2: 147
L EBV in aetiology of S1: 7, S1: 39, S1: 105, S1: 113
lenograstim (see G-CSF) elderly patients and lymphoma 873
lentaron (see formestane) epidemiology of S1: 19
leukemia fludarabine in lymphoma S2: 79
and acute lysis syndrome 379 genetic lesions associated with $1: 55, S1: 61
and lymphomas 689 growth inhibition of follicular small-cleaved-cell by IL-3 265
and primary mediastinal germ cell tumour 649 in children S1: 31
and regulation of chemoresistance by the bcl-2 oncoprotein S1: 61 in immunodeficiency $2: 29
heterogeneity of ALL in HIV-patients 437 low-grade: state-of-the-art $2: 23
possible treatment by immunotoxins S1: 97 MACOP-B in the treatment of $2: 91
treatment of secondary leukemias 401 mediastinal B-cell with sclerosis 943
levamisole modern treatment of 689, S2: 5
in the adjuvant therapy of colon adenocarcinoma S3: 97 nasal T-cell $1: 39
Leydig cell function primary mediastinal lymphoma 847, 943
dose-dependent impairment of function in patients treated with prognostic factors in 49, 689, 873, S2: 47, S2: 91
cisplatin 355 prognostic factors in HIV-related lymphoma S2: 45
LH-RH analogs P-VEBEC for elderly patients 895
ovarian ablation vs. goserelin with or without tamoxifen in advanced pro-MACE-MOPP vs. CHVmP-VB in S2: 85
breast cancer 337 quantitation of cells carrying t(14;18) S1: 43
limited sampling model randomized comparison of 4 drug combinations (SWOG-8516) S2: 91
for topotecan pharmacokinetics 259 recent progress in (Commentary) 689
general principles S4: 9, $4: 67 regulation of chemoresistance by the bcl-2 oncoprotein in S1: 61
low-grade lymphoma (see lymphomas) relationship with Hodgkin’s disease S1: 7
lung cancer (see also non-small-cell, small-cell lung cancer) reversion to negative of peripheral blood bcl-2 rearrangement S2: 73
a four drug combination in NSCLC 641 therapeutic use of antisense in S1: 67
a randomized trial of 3 combinations in SCLC 921 treatment of low-grade S2: 23, $2: 67
comparison of MVP vs. MIP in NSCLC 323 VACOP-B in mediastinal lymphoma 943
efficacy of chemotherapy in NSCLC 303 weekly VAPEC-B in aggressive lymphoma 147
etoposide and carboplatin or cisplatin in SCLC 601 lymphomatoid granulomatosis
extrapulmonary small-cell cancer 909 as a nasal T-cell lymphoma S1: 39
gemcitabine in SCLC 283
interferon and cis-retinoic acid in the treatment of 463 M
low dose radiotherapy in SCLC 771 m-BACOD
NSE compared to fucosyl-GM_, in SCLC 623 compared to CHOP, ProMACE-cytaBOM and MACOP-B S82: 91
phase I study of somatuline 290 M-VAC
phase II of elsamitrucin in NSCLC 375 in locally advanced, locally recurrent or metastatic breast carcinoma
phase II of gemcitabine in NSCLC 852 93
taxol in the treatment of S6: 45 in primary and metastatic transitional cell carcinoma of the bladder
vinorelbine alone or with cisplatin: a randomized trial in NSCLC 37 835
weekly carboplatin and VM-26 for elderly with SCLC 369 MACOP-B
lymphokine compared to CHOP, mBACOD and proMACE-cytaBOM §2: 91
receptors as a target for immunotherapy S1: 13 magnetic resonance imaging
lymphoma and Gallium scan in lymphoma 433
ABMT as consolidation for follicular lymphoma $2: 143 in radiological imaging related to oncology S4: 3
ABMT in the treatment of $2: 143, $2: 147, S2: 151, S2: 155 male breast cancer
anaplastic large-cell lymphoma 300, 317, S1: 25, S1: 31 and its management (Clinical cases) $4: 3
and biology of bel-2 199, S1: 61 mantle-cell lymphoma
and immunotoxins $1: 97 bcl-1 rearrangement in 507, S1: 71
bel-1 by mantle cell 507, $1: 51, $1: 71 clinical-pathologic basis $1: 35
2-cDA in lymphoma 57 consensus paper on 507
chlorambucil vs. CHOP in low-grade S2: 67 cyclin D1 overexpression in S!: 71
CHOP vs. 3 other combinations $2: 91 MDR